Medicine and Dentistry
Human Immunodeficiency Virus
100%
Antiretroviral Therapy
100%
Lamivudine
100%
Observational Study
66%
Proteinase Inhibitor
66%
Public Health
16%
Randomized Controlled Trial
16%
Symptom
16%
Adverse Event
16%
Thymidine
16%
Reverse-Transcriptase Inhibitor
16%
HIV/AIDS
16%
Systematic Review
16%
Cell Count
16%
Adolescent
16%
Nonnucleoside Reverse Transcriptase Inhibitor
16%
Highly Active Antiretroviral Therapy
16%
Nucleoside
16%
Emtricitabine
16%
Spine
16%
Nursing and Health Professions
Human Immunodeficiency Virus
100%
Antiretroviral Therapy
100%
Lamivudine
100%
Proteinase Inhibitor
66%
World Health Organization
33%
Virus Load
16%
CD4 Lymphocyte Count
16%
Highly Active Antiretroviral Therapy
16%
Symptom
16%
Adolescent
16%
Treatment Failure
16%
Adverse Event
16%
Systematic Review
16%
Nonnucleoside Reverse Transcriptase Inhibitor
16%
RNA Directed DNA Polymerase Inhibitor
16%
Thymidine
16%
Emtricitabine
16%
Nucleoside
16%
Pharmacology, Toxicology and Pharmaceutical Science
HIV
100%
Lamivudine
100%
Observational Study
66%
Proteinase Inhibitor
66%
Adverse Event
16%
Randomized Controlled Trial
16%
Symptom
16%
Thymidine
16%
RNA Directed DNA Polymerase Inhibitor
16%
Nonnucleoside Reverse Transcriptase Inhibitor
16%
Nucleoside
16%
Emtricitabine
16%
Keyphrases
First-line ART
20%
Second-line ART
20%